Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Τίτλος | Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density? |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Koletsa, T., Kotoula V., Koliou G-A., Manousou K., Chrisafi S., Zagouri F., Sotiropoulou M., Pentheroudakis G., Papoudou-Bai A., Christodoulou C., Xepapadakis G., Zografos G., Petraki K., Pazarli E., Koutras A., Kourea H. P., Bafaloukos D., Chatzopoulos K., Iliadis A., Markopoulos C., Venizelos V., Arnogiannaki N., Kalogeras K. T., Kostopoulos I., Gogas H., & Fountzilas G. |
Journal | Cancer Immunol Immunother |
Date Published | 2020 Apr 18 |
ISSN | 1432-0851 |
Abstract | BACKGROUND: Tumor-infiltrating lymphocytes (TILs) and their subsets contribute to breast cancer prognosis. We investigated the prognostic impact of CD3+, CD8+ and FOXP3+ TILs in patients with early intermediate/high-risk breast cancer treated with adjuvant anthracycline-based chemotherapy within two randomized trials conducted by our Group. |
DOI | 10.1007/s00262-020-02557-0 |
Alternate Journal | Cancer Immunol. Immunother. |
PubMed ID | 32303794 |
Grant List | HE TRANS_BR / / Hellenic Cooperative Oncology Group (HeCOG) / |